

Massachusetts General Hospital Corporate & Foundation Relations Office of Development

PRIVATE FUNDING OPPORTUNITIES: MAR 10, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than <u>15% in indirect costs (IDC)</u> will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submission of the award. <u>Training fellowships</u> from foundations, public charity, and non-profit organizations <u>are excluded</u> from this minimum IDC requirement.

1. AARP Foundation Grant Competition: Identifying Evidence-Based Solutions for Vulnerable Older Adults, American Association of Retired Persons (AARP) Foundation

AARP Foundation works to ensure that low-income vulnerable older adults have nutritious food, safe, secure and affordable housing, a steady income, and strong and sustaining social bonds. To address those needs, the grant competition is seeking evidence-based solutions that are guided by a deep level of engagement with AARP Foundation and that can be nurtured, evaluated and brought to scale.

Through this grant competition the Foundation hopes to achieve multiple goals:

- Create a portfolio of grant-funded programs that includes projects with different levels
 of evidence with the goal of scaling, at the appropriate time, to serve more low-income
 older adults
- Identify solutions that seek to achieve a double bottom line (sustainable programs that achieve a positive financial and social return).

Ultimately, the Foundation expects a percentage of the selected grantees will increase their level of evidence in preparation to scale their programs nationally. AARP Foundation will be actively involved during the grant period to understand how each grant-funded program works and how the Foundation can provide the necessary technical assistance to reach the different levels of evidence and create a model to achieve sustainability and expansion.

Award Amount:

- Theory of Change/ Pre-Evidence: \$50,000-\$75,000; 9-18 months
- Self-reported Evidence: \$100,000-\$200,000/year; 18-24 months
- Independent Evaluation: \$200,000-\$300,000/year; 24-36 months



Indirect Costs: None

Pre-Application Deadline: Apr 7, 2017 (Sandpit briefing session: Mar 14, 2017)

Website: http://www.aarp.org/aarp-foundation/grants/info-2016/Identifying-Evidence-Based-

Solutions.html

2. Joseph E. Wagstaff Postdoctoral Fellowship Grant, Angelman Syndrome Foundation, Inc. (ASF)

Dr. Joseph E. Wagstaff was a consummate pediatrician, medical geneticist and researcher. As much as anyone in the world, he advanced our scientific understanding of the Angelman syndrome (AS). He also diagnosed and treated scores of children and adults with AS and selflessly gave of his time to provide much needed counsel to their families. Dr. Wagstaff was also an invaluable contributor to the ASF and his work on the Scientific Advisory Committee was instrumental in soliciting and evaluating the high caliber of scientific proposals that ASF is proud to fund. Dr. Wagstaff dedicated his life to the benefit and compassionate care of his patients and support of their families. Through this grant the ASF seeks to honor Dr. Wagstaff's legacy by supporting clinical and basic science research on the Angelman syndrome.

The ASF strives to improve the lives of those with Angelman syndrome and their families by supporting research on the clinical and basic science aspects of the Angelman syndrome. ASF seeks applications for postdoctoral fellowships in the preclinical, translational and clinical research areas that investigate all aspects of Angelman syndrome. The purpose of this award is to:

- Promote Angelman syndrome-related research in a young investigator
- Support novel or innovative research initiatives

Further support and encourage existing Angelman-related research projects

Award Amount: \$110,000 paid over 2 years

Indirect Costs: None

Application Deadline: Mar 17, 2017

Website: http://www.angelman.org/research/joseph-e-wagstaff-postdoctoral-fellowship/

3. Grants, Gladys Brooks Foundation

Grant Funding for Hospitals and Clinics: Grant applications from hospitals and clinics will be considered generally where the proposal demonstrates one or more of the following: (a) a new health need; (b) an improvement in the quality of health care; or (c) reduced health costs with better patient outcomes. Generally, no grant will be considered that is to support a laboratory research project. Proposals for a continuing project must include a commitment from the applicant or a third party that the project will continue to receive all the necessary financial support after the grant from the Foundation is expended.

Grant applications generally will be considered where: (a) outside funding (including governmental) is not available; (b) the project will be largely funded by the grant unless the grant request covers a discrete component of a larger project; and (c) the funds will be used for capital projects including equipment or endowments.

Award Amount: \$50,000-\$100,000

Indirect Costs: None

Application Deadline: May 31, 2017

Website: http://www.gladysbrooksfoundation.org/guidelines.html

4. Postdoctoral Research Fellowships, Cystinosis Research Foundation

The ultimate goal of the CRF is a cure for cystinosis. The CRF has launched a postdoctoral research fellowship program to attract qualified, promising investigators to establish careers in cystinosis research. The Foundation will support bench, translational and clinical research.

Award Amount: Up to \$225,000 paid over 1-3 years

Indirect Costs: 10%

Proposal Deadline: Apr 10, 2017

Website: http://www.cystinosisresearch.org/research/for-researchers/

5. Greater Value Portfolio, Patrick and Catherine Weldon Donaghue Medical Research Foundation

The Donaghue Foundation announces its 2017 Greater Value Portfolio grant program that will fund research projects for the purpose of creating new approaches to achieving a higher value healthcare system. The goal of this program is to test new approaches and tools that organizations can readily use to improve the value of the healthcare they provide to their patients and communities.

The Foundation believes value in health care is achieved with uniformly high quality outcomes and favorable patient experience for the money we spend. Symptoms of poor healthcare value are high and rising healthcare costs, unwarranted variation in prices, unacceptable variation in quality, and a lack of transparency in both price and outcomes. Investigators conducting research that expect to develop actionable solutions to one or more of these symptoms of low value healthcare are encouraged to apply to the Greater Value Portfolio program.

Eligible topics include research concerning the following strategies:

- Efforts that significantly increase the value of traditionally high-cost procedures through mechanisms such as medical tourism or specialty treatment centers
- Methods or approaches that reduce routine treatments, tests, and screenings for patients for whom the potential harms (including financial harm) outweigh potential benefits

- Provide consumers with the tools to make decisions about their healthcare that are based on value in addition to other patient-centered factors
- Encourage providers and their patients with serious illnesses to engage in difficult conversations about preferences and trade-offs related to alternative treatment options
- Identify, highlight and resolve structural disincentives to greater value or inefficiencies within systems or across healthcare settings
- Create economic models that address current financial disincentives for systemic change (i.e., paying for current programs with future savings or paying for social determinants of health with the savings from lower clinical services)
- Worthy, inexpensive clinical interventions that are currently underused

In order to receive the award, the applicant must demonstrate how their research question is important to relevant stakeholders, how answers to their questions will lead to practical benefit in bringing greater value to health and healthcare, and propose a rigorous research design.

Topics that are not considered relevant to the purpose of the program are efficacy trials, comparative effectiveness research that does not include cost analysis, basic research, or research using animal models.

Award Amount: \$600,000 paid over 3-5 years

Indirect Costs: 10%

LOI Deadline: May 1, 2017

Website: http://donaghue.org/grant-programs/grant-opportunities/

6. Pediatric Research Grants, Gerber Foundation

The Foundation's mission focuses on the nutrition, care and development of infants and young children. Therefore, grant-making interests are focused on health and/or nutrition-related research having a significant impact on issues facing infants and young children from the first year before birth to age 3.

The Foundation is particularly interested in fresh approaches to solving newborn or pediatric problems or emerging issues with a predictable time frame to clinical application. Projects should be focused on issues faced by care providers that, when implemented, will improve the health, nutrition and/or developmental outcomes for infants and young children. Projects may include:

- Etiologic mechanisms of disease
- New, improved or less invasive diagnostic procedures
- Reduction or elimination of side effects
- Alleviation of symptoms
- New, improved or less invasive therapies, care, or treatments
- Dosage or dosing requirements or mechanisms for drugs, nutrient supplementation or other therapeutic measures (under or overdosing)

• Preventative measures

The Foundation gives priority to projects of national or regional impact.

The foundation offers research grants in the following categories:

PEDIATRIC HEALTH: Promoting health and preventing or treating disease is the primary focus of this target area. Of particular interest are applied research projects focused on reducing the incidence of serious neonatal and early childhood illnesses, or improving cognitive, social and emotional aspects of development.

PEDIATRIC NUTRITION: These programs respond to a long-time interest of the Foundation in assuring adequate nutrition for infants and young children. Projects include applied research that evaluates the provision of specific nutrients and their related outcomes in infants and young children.

ENVIRONMENTAL HAZARDS (NUTRIENT COMPETITORS) The Foundation is interested in projects that evaluate the effects of environmental hazards on infants and young children. Applied research projects that document the impact of, or ameliorate effects of, environmental hazards on the growth and development of infants and young children are the focus of this area of interest.

Award Amount: \$350,000 paid over 3 years

Indirect Costs: 10%

Concept Paper Deadline: Jun 1, 2017

Website: http://www.gerberfoundation.org/how-to-apply/

7. Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Clinical Advances in Merkel Cell Carcinoma (MCC) Supporting Local and Regional Activities for Community Oncologists, Pfizer, Inc.

Pfizer - Independent Grants for Learning & Change (IGLC) and EMD Serono Global Medical Education (GME) are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology.

MCC is a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings. MCC, which is also known as neuroendocrine carcinoma of the skin or trabecular cancer, often starts in those areas of skin that are most often exposed to the sun, including the head and neck, arms, legs, and trunk. Risk factors for MCC include sun exposure and having a weak immune system. Solid organ transplant recipients, people with HIV/AIDS and people with other cancers, such as chronic lymphocytic leukemia, are at higher risk. Caucasian males over age 50 are also at increased risk. MCC tends to metastasize at an early stage, spreading initially to nearby lymph nodes, and then potentially to more distant areas in the body, including other lymph nodes or areas of skin, lungs, brain, bones or other organs.

Current treatment options for MCC include surgery, radiation and chemotherapy. Treatment for metastatic or Stage IV MCC is generally palliative. A variety of investigative immunotherapy options for MCC are being explored worldwide.

Clinical Area: Merkel Cell Carcinoma (MCC)

Geographic Scope: United States Only

Specific Area of Interest for this CGA:

Pfizer IGLC and EMD Serono GME are collaborating to support independent education for community oncologists that focuses on increasing the awareness and detection of MCC, managing immunemediated adverse reactions, and advancing the understanding of emerging treatment options for patients with MCC, including, without limitation, immunotherapy.

This CGA is requesting grant applications for proposals that will help community oncologists stay abreast of emerging data in MCC and emerging treatment options. Proposals may include activities such as:

- On-agenda sessions at established conferences
- Mini symposia alongside established conferences
- Regional live meetings, workshops, grand rounds, tumor board presentations, etc.
- Online tools, printed handouts, and other enduring materials

The content and/or the format of the activities and the related materials must be designed in such a way that they addresses the evolving educational needs of health care professionals and, if appropriate, tools/aids that can help health care professionals diagnose MCC, manage immune-mediated adverse reactions, and better communicate with and manage their patients.

Proposals may include scientific course content on a wide range of topics from understanding the science of mechanisms of action of emerging treatment options to more practical information for clinical application using MCC patient-case-based discussions.

All activities must be "independent" which means free from the influence or control of any commercial entity. Activities must also be accredited/certified for CME/CE credit.

Award Amount: \$75,000 for 1 year

Indirect Costs: 28%

Application Deadline: Apr 5, 2017

Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

8. Pfizer Independent Grants for Learning & Change (IGLC): Request for Proposals (RFP) - Rheumatology Fellowships, Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through

support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

The Pfizer Fellowship Program ("Fellowship Program") is a reflection of Pfizer's commitment to advancing research, innovation, clinical expertise and medical education for medical, nursing, and allied health professionals. This program provides career-building opportunities for practicing clinicians and academic researchers in outcomes and patient-oriented research that is vital to improving healthcare.

The intent of this Request for Proposal (RFP) is to encourage organizations with an active rheumatology fellowship program to submit a proposal. The purpose of the Fellowship Program grant is to provide support the continued training of fellows in any year of a program focused on research. Organizations seeking funding must submit proposals describing the strength of their program in supporting clinical training and research.

Geographic scope: United States Only

Clinical area: Rheumatology

Specific Area of Interest: It is Pfizer's intent to support institutions with adult rheumatology fellowship programs that have a strong focus on clinical practice, research, and education to further the understanding of rheumatic diseases.

Grants will be awarded based on the strength of the requesting organization's ability to provide training and guidance to the fellow. Priority will be given to applications demonstrating the most need.

Requirements for Prospective Fellows

- Prospective award recipients at the organization cannot apply directly for the award.
 However, a fellow may assist the senior staff, division head or department chair at the organization in the development of the application.
- Fellows supported by a Pfizer fellowship must have the opportunity to carry out supervised research with the primary objective preparation for their respective discipline and subspecialty.
- Upon receipt of the award, the fellow selected by the organization must meet the following criteria: U.S. citizen or foreign national with permanent U.S. residence; hold an advanced degree (e.g., PhD, MD, DO, NP, PharmD, etc.).

Requirements for Research Projects

This grant opportunity is to support fellows involved with independent research that seeks to improve the organization, financing and/or delivery of strategies and initiatives that promote

health and prevent disease and disability in patients with rheumatic diseases. Examples of such research include, but are not limited to: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; novel approaches to implementing improvements in practice; use of screening tools and their impact on improvement of patient health. Examples of research that would be ineligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, invitro, etc.).

Award Amount: \$160,000 paid over 2 years

Indirect Costs: 28%

Application Deadline: Mar 24, 2017

Website: http://www.pfizer.com/responsibility/grants contributions/request proposals